tetano
Editor, Senior Moderator
Nature
. 2020 Jul 29.
doi: 10.1038/s41586-020-2599-8. Online ahead of print.
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
Jingyun Yang[SUP] 1 [/SUP], Wei Wang[SUP] 1 [/SUP], Zimin Chen[SUP] 1 [/SUP], Shuaiyao Lu[SUP] 2 [/SUP], Fanli Yang[SUP] 1 [/SUP], Zhenfei Bi[SUP] 1 [/SUP], Linlin Bao[SUP] 3 [/SUP], Fei Mo[SUP] 1 [/SUP], Xue Li[SUP] 1 [/SUP], Yong Huang[SUP] 1 [/SUP], Weiqi Hong[SUP] 1 [/SUP], Yun Yang[SUP] 2 [/SUP], Yuan Zhao[SUP] 2 [/SUP], Fei Ye[SUP] 1 [/SUP], Sheng Lin[SUP] 1 [/SUP], Wei Deng[SUP] 3 [/SUP], Hua Chen[SUP] 1 [/SUP], Hong Lei[SUP] 1 [/SUP], Ziqi Zhang[SUP] 1 [/SUP], Min Luo[SUP] 1 [/SUP], Hong Gao[SUP] 3 [/SUP], Yue Zheng[SUP] 1 [/SUP], Yanqiu Gong[SUP] 1 [/SUP], Xiaohua Jiang[SUP] 1 [/SUP], Yanfeng Xu[SUP] 3 [/SUP], Qi Lv[SUP] 3 [/SUP], Dan Li[SUP] 1 [/SUP], Manni Wang[SUP] 1 [/SUP], Fengdi Li[SUP] 3 [/SUP], Shunyi Wang[SUP] 3 [/SUP], Guanpeng Wang[SUP] 3 [/SUP], Pin Yu[SUP] 3 [/SUP], Yajin Qu[SUP] 3 [/SUP], Li Yang[SUP] 1 [/SUP], Hongxin Deng[SUP] 1 [/SUP], Aiping Tong[SUP] 1 [/SUP], Jiong Li[SUP] 1 [/SUP], Zhenling Wang[SUP] 1 [/SUP], Jinliang Yang[SUP] 1 [/SUP], Guobo Shen[SUP] 1 [/SUP], Zhiwei Zhao[SUP] 1 [/SUP], Yuhua Li[SUP] 4 [/SUP], Jingwen Luo[SUP] 1 [/SUP], Hongqi Liu[SUP] 2 [/SUP], Wenhai Yu[SUP] 2 [/SUP], Mengli Yang[SUP] 2 [/SUP], Jingwen Xu[SUP] 2 [/SUP], Junbin Wang[SUP] 2 [/SUP], Haiyan Li[SUP] 2 [/SUP], Haixuan Wang[SUP] 2 [/SUP], Dexuan Kuang[SUP] 2 [/SUP], Panpan Lin[SUP] 1 [/SUP], Zhengtao Hu[SUP] 5 [/SUP], Wei Guo[SUP] 5 [/SUP], Wei Cheng[SUP] 1 [/SUP], Yanlin He[SUP] 5 [/SUP], Xiangrong Song[SUP] 1 [/SUP], Chong Chen[SUP] 1 [/SUP], Zhihong Xue[SUP] 1 [/SUP], Shaohua Yao[SUP] 1 [/SUP], Lu Chen[SUP] 1 [/SUP], Xuelei Ma[SUP] 1 [/SUP], Siyuan Chen[SUP] 1 [/SUP], Maling Gou[SUP] 1 [/SUP], Weijin Huang[SUP] 4 [/SUP], Youchun Wang[SUP] 4 [/SUP], Changfa Fan[SUP] 4 [/SUP], Zhixin Tian[SUP] 6 [/SUP], Ming Shi[SUP] 7 [/SUP], Fu-Sheng Wang[SUP] 7 [/SUP], Lunzhi Dai[SUP] 1 [/SUP], Min Wu[SUP] 1 [/SUP], Gen Li[SUP] 8 [/SUP], Guangyu Wang[SUP] 9 [/SUP], Yong Peng[SUP] 1 [/SUP], Zhiyong Qian[SUP] 1 [/SUP], Canhua Huang[SUP] 1 [/SUP], Johnson Yiu-Nam Lau[SUP] 10 [/SUP], Zhenglin Yang[SUP] 11 [/SUP], Yuquan Wei[SUP] 1 [/SUP], Xiaobo Cen[SUP] 1 5 [/SUP], Xiaozhong Peng[SUP] 2 [/SUP], Chuan Qin[SUP] 3 [/SUP], Kang Zhang[SUP] 12 [/SUP], Guangwen Lu[SUP] 13 14 [/SUP], Xiawei Wei[SUP] 15 [/SUP]
Affiliations
Abstract
The novel Coronavirus SARS-CoV-2 causes a respiratory illness called COVID-19 leading to a pandemic. An effective preventive vaccine against this virus is urgently needed. As the most critical step during infection, SARS-CoV-2 uses its Spike protein receptor-binding domain (S-RBD) to engage with the host cell receptor angiotensin-converting enzyme 2 (ACE2)[SUP]1,2[/SUP]. Here we showed that a recombinant vaccine comprising residues 319-545 of the S-RBD could induce a potent functional antibody response in the immunized mice, rabbits and non-human primates (Macaca mulatta) as early as 7 or 14 days after a single dose injection. The sera from the immunized animals blocked RBD binding to ACE2 expressed on the cell surface and neutralized the infection by SARS-CoV-2 pseudovirus and live SARS-CoV-2 in vitro. Importantly, the vaccination also provided protection in non-human primates from SARS-CoV-2 challenge in vivo. The elevated RBD-specific antibodies were also found in the sera from patients with COVID-19. Several immune pathways and CD4 T lymphocytes were implicated in the induction of the vaccine antibody response. Our finding highlights the importance of the RBD domain in the SARS-CoV-2 vaccine design and provides the rationale for the development of a protective vaccine through the induction of antibody against the RBD domain.
. 2020 Jul 29.
doi: 10.1038/s41586-020-2599-8. Online ahead of print.
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
Jingyun Yang[SUP] 1 [/SUP], Wei Wang[SUP] 1 [/SUP], Zimin Chen[SUP] 1 [/SUP], Shuaiyao Lu[SUP] 2 [/SUP], Fanli Yang[SUP] 1 [/SUP], Zhenfei Bi[SUP] 1 [/SUP], Linlin Bao[SUP] 3 [/SUP], Fei Mo[SUP] 1 [/SUP], Xue Li[SUP] 1 [/SUP], Yong Huang[SUP] 1 [/SUP], Weiqi Hong[SUP] 1 [/SUP], Yun Yang[SUP] 2 [/SUP], Yuan Zhao[SUP] 2 [/SUP], Fei Ye[SUP] 1 [/SUP], Sheng Lin[SUP] 1 [/SUP], Wei Deng[SUP] 3 [/SUP], Hua Chen[SUP] 1 [/SUP], Hong Lei[SUP] 1 [/SUP], Ziqi Zhang[SUP] 1 [/SUP], Min Luo[SUP] 1 [/SUP], Hong Gao[SUP] 3 [/SUP], Yue Zheng[SUP] 1 [/SUP], Yanqiu Gong[SUP] 1 [/SUP], Xiaohua Jiang[SUP] 1 [/SUP], Yanfeng Xu[SUP] 3 [/SUP], Qi Lv[SUP] 3 [/SUP], Dan Li[SUP] 1 [/SUP], Manni Wang[SUP] 1 [/SUP], Fengdi Li[SUP] 3 [/SUP], Shunyi Wang[SUP] 3 [/SUP], Guanpeng Wang[SUP] 3 [/SUP], Pin Yu[SUP] 3 [/SUP], Yajin Qu[SUP] 3 [/SUP], Li Yang[SUP] 1 [/SUP], Hongxin Deng[SUP] 1 [/SUP], Aiping Tong[SUP] 1 [/SUP], Jiong Li[SUP] 1 [/SUP], Zhenling Wang[SUP] 1 [/SUP], Jinliang Yang[SUP] 1 [/SUP], Guobo Shen[SUP] 1 [/SUP], Zhiwei Zhao[SUP] 1 [/SUP], Yuhua Li[SUP] 4 [/SUP], Jingwen Luo[SUP] 1 [/SUP], Hongqi Liu[SUP] 2 [/SUP], Wenhai Yu[SUP] 2 [/SUP], Mengli Yang[SUP] 2 [/SUP], Jingwen Xu[SUP] 2 [/SUP], Junbin Wang[SUP] 2 [/SUP], Haiyan Li[SUP] 2 [/SUP], Haixuan Wang[SUP] 2 [/SUP], Dexuan Kuang[SUP] 2 [/SUP], Panpan Lin[SUP] 1 [/SUP], Zhengtao Hu[SUP] 5 [/SUP], Wei Guo[SUP] 5 [/SUP], Wei Cheng[SUP] 1 [/SUP], Yanlin He[SUP] 5 [/SUP], Xiangrong Song[SUP] 1 [/SUP], Chong Chen[SUP] 1 [/SUP], Zhihong Xue[SUP] 1 [/SUP], Shaohua Yao[SUP] 1 [/SUP], Lu Chen[SUP] 1 [/SUP], Xuelei Ma[SUP] 1 [/SUP], Siyuan Chen[SUP] 1 [/SUP], Maling Gou[SUP] 1 [/SUP], Weijin Huang[SUP] 4 [/SUP], Youchun Wang[SUP] 4 [/SUP], Changfa Fan[SUP] 4 [/SUP], Zhixin Tian[SUP] 6 [/SUP], Ming Shi[SUP] 7 [/SUP], Fu-Sheng Wang[SUP] 7 [/SUP], Lunzhi Dai[SUP] 1 [/SUP], Min Wu[SUP] 1 [/SUP], Gen Li[SUP] 8 [/SUP], Guangyu Wang[SUP] 9 [/SUP], Yong Peng[SUP] 1 [/SUP], Zhiyong Qian[SUP] 1 [/SUP], Canhua Huang[SUP] 1 [/SUP], Johnson Yiu-Nam Lau[SUP] 10 [/SUP], Zhenglin Yang[SUP] 11 [/SUP], Yuquan Wei[SUP] 1 [/SUP], Xiaobo Cen[SUP] 1 5 [/SUP], Xiaozhong Peng[SUP] 2 [/SUP], Chuan Qin[SUP] 3 [/SUP], Kang Zhang[SUP] 12 [/SUP], Guangwen Lu[SUP] 13 14 [/SUP], Xiawei Wei[SUP] 15 [/SUP]
Affiliations
- PMID: 32726802
- DOI: 10.1038/s41586-020-2599-8
Abstract
The novel Coronavirus SARS-CoV-2 causes a respiratory illness called COVID-19 leading to a pandemic. An effective preventive vaccine against this virus is urgently needed. As the most critical step during infection, SARS-CoV-2 uses its Spike protein receptor-binding domain (S-RBD) to engage with the host cell receptor angiotensin-converting enzyme 2 (ACE2)[SUP]1,2[/SUP]. Here we showed that a recombinant vaccine comprising residues 319-545 of the S-RBD could induce a potent functional antibody response in the immunized mice, rabbits and non-human primates (Macaca mulatta) as early as 7 or 14 days after a single dose injection. The sera from the immunized animals blocked RBD binding to ACE2 expressed on the cell surface and neutralized the infection by SARS-CoV-2 pseudovirus and live SARS-CoV-2 in vitro. Importantly, the vaccination also provided protection in non-human primates from SARS-CoV-2 challenge in vivo. The elevated RBD-specific antibodies were also found in the sera from patients with COVID-19. Several immune pathways and CD4 T lymphocytes were implicated in the induction of the vaccine antibody response. Our finding highlights the importance of the RBD domain in the SARS-CoV-2 vaccine design and provides the rationale for the development of a protective vaccine through the induction of antibody against the RBD domain.